

ABSTRACT TEMPLATE: CHECKLIST AND INSTRUCTIONS

Company name Modulight.bio * Website www.modulight.bio *

CEO name Yotam Eldar * Cell phone number

CATEGORY: Biotech

SESSIONS

- Rewiring the Brain; Breakthroughs in Neurotech and Neuromodulation
- **Executive Summary / Investment Rational:** *Modulight.bio is pioneering a precision neuromodulation platform for severe neurological disorders. Backed by \$7 million in seed funding, we've achieved in vivo proof-of-concept across multiple disease models. With strategic partnerships at Mayo Clinic, Sheba, and Harvard, and backed by world-class advisors and a seasoned leadership team, Modulight.Bio is positioned to transform treatment in high-value, underserved markets.*
- **Core Technology:** *Modulight.bio's core technology is a proprietary **optogenetic neuromodulation platform** that enables precise, light-driven control of dysfunctional brain circuits. Our lead therapeutic agent, a **next-generation light-switchable protein (opsin)** has unparalleled sensitivity and kinetics, and is uniquely suited for clinical applications. Our scalable precision neuromodulation platform targets major unmet clinical needs in **neuropathic pain, drug-resistant epilepsy, and movement disorders**.*
- **Product Profile/Pipeline:** *Modulight.bio's platform targets severe neurological disorders, led by our trigeminal neuropathic pain program. Neuropathic pain represents an enormous unmet need with a multi-billion dollar market opportunity for differentiated, non-opioid therapies. We have already demonstrated strong proof-of-concept efficacy, and are advancing toward IND-enabling studies, leveraging partnerships with strong clinical and academic collaborators in the US, Europe, and Israel.*
- **Business Strategy:** *Modulight.bio will first target a severe, rare neurological indication to enable an expedited regulatory pathway and early clinical validation. Success will position the platform for expansion to larger markets. Revenue will be generated through strategic partnerships, out-licensing, and eventually commercialization. Ongoing innovation will drive pipeline growth and support long-term value creation across multiple therapeutic areas.*
- **What's Next?:** *Modulight.Bio is completing early development and preparing for IND-enabling activities. We are gearing up to launch a series A to fund preclinical and First-in-Human trials.. **It is our privilege to advance transformative treatments with the potential to restore health and quality of life for millions affected by severe neurological disorders.***